Organon Medicine - Search News

Organon, Roivant

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click here to read my most recent analysis.

Reuters · 6d

Organon to buy Roivant's dermatology unit for up to $1.2 billion

"We are excited for Vtama cream to benefit from Organon's commercial scale. We believe they have the capabilities and reach to ensure patients globally can access this important medicine," said Roivant's CEO Matt Gline. Vtama generated net product revenue ...

NJBIZ · 5d

Organon to acquire Dermavant in $1.2B deal

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

YAHOO!Finance · 6d

Roivant dermatology subsidiary to be acquired by Organon

The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.

MarketWatch · 6d

Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion

Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million,

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

STAT6d

Bernie Sanders keeps the heat on Novo’s high prices

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

MedCity News7d

Organon Gets More Skin in the Game by Acquiring Roivant’s Dermatology Subsidiary

Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to ...

Benzinga.com6d

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Also Read: JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability. The FDA is reviewing a supplemental application for Vtama cream as a potential ...

Business Insider6d

Assessing Organon’s Strategic Acquisition of Dermavant: A Balanced Hold Recommendation Amid Growth and Challenges

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of $18.00. Terence Flynn’s rating is based on the potential and ...

Morningstar7d

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

we are excited for VTAMA cream to benefit from Organon’s commercial scale. We believe they have the capabilities and reach to ensure patients globally can access this important medicine.” ...

Yahoo Finance6d

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results